This editorial refers to 'Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol' † , by G.R. Thompson et al., on page 1162.
Homozygous familial hypercholesterolaemia (HoFH) is one of the most extreme forms of hereditary lipoprotein disorders. One only has to refer to the numerous published case reports to gain an appreciation of the dramatic consequences of HoFH. Patients typically experience a first major cardiovascular event during adolescence or early adulthood, and cholesterol levels can be elevated to such an extent that depositions in the form of xanthomata may already be present at birth. 1 Large variation in the phenotypical expression of HoFH does exist, and cases of death and the need for major cardiovascular surgery during early childhood have been described. 2 The implementation of screening programmes for FH and advances in genetics have revealed that HoFH is three-to four-fold more common than the traditional estimate of one in a million. 3 However, much higher rates of up to 1:30 000 have been reported in some populations due to founder effects and consanguinity. 3 The advent of statin therapy and ezetimibe has substantially improved the outcomes for HoFH patients. In the pre-statin era, there was little more that clinicians could do than to advise patients to adhere to a low-fat diet, combined with minimally effective lipidlowering drugs, two interventions with very limited effect on LDL cholesterol levels. In addition, apheresis could be started, or a liver transplantation performed, The statin revolution in the 1990s finally provided the means to change the course of HoFH-no longer did clinicians have to stand by and watch patients succumb to the detrimental consequences of 'plasma dissolved in cholesterol'. Little over a decade later, in the early 2000s, the introduction of the cholesterol absorption inhibitor ezetimibe presented another addition to the armamentarium in the fight against HoFH. Although clinical trial evidence to demonstrate the placebo-controlled effects of statins and ezetimibe in HoFH is not available for obvious ethical reasons, retrospective analyses comparing event rates before and after introduction of these therapies are revealing. For example, Raal et al. reported a hazard ratio of benefit from therapy of 0.34 for death. 4 Recent years have experienced the second revolution in the pharmacological treatment of dyslipidaemia after statins, in the form of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These drugs enable the majority of high-risk patients to reach unprecedented low LDL cholesterol levels. The curse of HoFH is, however, that both statins and PCSK9 inhibitors are less effective than in nonHoFH patients because both therapies work by virtue of increased expression of the LDL receptor, which is functionally impaired in HoFH. The magnitude of the achieved LDL reduction with statins and PCSK9 inhibitors depends on residual LDL receptor functionpatients without residual function typically do not respond to PCSK9 inhibitors. 5 Nonetheless, for the majority of HoFH patients (90%) who do have residual LDL receptor activity, high-dose statins typically reduce LDL cholesterol in HoFH patients by 10-25%, ezetimibe by 10-15%, and PCSK9 inhibitors by 20-30%.
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These still modest percentages, combined with the observation that HoFH patients typically have untreated LDL cholesterol values >13 mmol/L, make it evident that even the combination of statins, ezetimibe, and PCSK9 inhibitors leaves the majority of patients with unacceptably high lipid levels and a sharply elevated risk of cardiovascular disease. Other treatment options include lipoprotein apheresis, mipomersen, and lomitapide. 7 Even if these treatments are effective, available, and reimbursed, they are cumbersome and have significant side effects. Patients and their physicians therefore face the daunting task of balancing residual cardiovascular risk against the burden of therapy. This makes it all the more clinically relevant to determine whether additional lipid lowering actually improves clinical outcomes for HoFH patients, as is shown for non-HoFH patients. Expert panels have recently taken the position that HoFH patients should ideally be treated to lipid goals similar to other high-risk patients, which is an impossible task with currently available treatment options. Prior retrospective cohort studies from South Africa and the UK showed substantial variation in the achieved on-therapy cholesterol levels for HoFH patients, and independently suggested a relationship between the achieved cholesterol reduction and survival. The authors now combined data from 133 genetically confirmed patients from both cohorts, who were followed for 25 years, to test formally the hypothesis of whether the extent of reduction in LDL cholesterol determines survival in HoFH patients.
Although recent studies have highlighted the phenotypic variability among HoFH patients, patients in the current study were generally severely affected, as reflected by the mean baseline total cholesterol of 18 mmol/L. Almost all patients used statins, 56% used ezetimibe, and 19% received apheresis. The devastating nature of HoFH is well reflected by the clinical outcomes of patients in the study: one-third died during the 25-year follow-up and 60% experienced a cardiovascular event, despite their young age. The survival analysis clearly showed that patients with lower on-treatment cholesterol levels had better survival and fewer cardiovascular events than patients with higher on-treatment cholesterol levels. After adjusting for pretreatment cholesterol levels, demographic characteristics, and differences in therapy, patients in the highest on-treatment cholesterol quartile had a six-fold increased risk of death compared with those in the lowest quartile. Thus, the extent of achieved lipid reduction per se determined clinical outcomes regardless of how this was accomplished. The variability of clinical outcomes was also revealing: almost 70% of patients in the highest on-treatment cholesterol quartile died during follow-up, compared with 9% in the lowest quartile.
Importantly, the risk of cardiovascular events was lower among patients who started treatment earlier in life.
Obtaining a large enough sample of patients to detect meaningful differences in clinical outcomes is always a challenge in studies of diseases as rare as HoFH. As such, the large variation in on-treatment serum cholesterol levels in the study by Thomson et al. is welcome from a methodological perspective. The retrospective nature of the study, as well as the heterogeneity in patient characteristics such as differences between those from the UK and South Africa, are obvious limitations. However, the magnitude of the effect which persisted after adjusting for important confounders, combined with the indisputable evidence of an association between the achieved therapeutic cholesterol reductions and longevity in non-HoFH patients, make the conclusions of the current study highly credible. 10 The clinical relevance of confirming the paradigm 'lower is better', as well as the contention 'earlier is better', also holds for HoFH patients is obvious: early recognition and prompt initiation of multimodal treatment saves lives-there is no excuse for a 'laid-back' or 'haphazard' approach. The risks and benefits of lipoprotein apheresis, lomitapide, or mipomersen should be weighed for the majority of patients who are unable to achieve acceptable lipid control with the standard regimen of high-dose statins and ezetimibe, even in combination with a PCSK9 inhibitor. Fortunately, several promising treatment options are under way, potentially heralding the 'third revolution' in the treatment of FH after statins and PCSK9 inhibitors.
First, evinacumab, a monoclonal antibody targeting ANGPTL3, has been shown to reduce LDL cholesterol by 49% in a study of nine HoFH patients against various background lipid-lowering therapies, and was remarkably well tolerated. 11 Importantly, the effect of A second promising approach is gemcabene, which reduces the synthesis of hepatic cholesterol, triglycerides, and apoC3. Several proof-of-concept phase II trials in non-HoFH populations have shown LDL cholesterol reductions of 30% when gemcabene was added to statins. Given that the drug works at least partially independently of the LDL receptor, gemcabene may be another valuable addition particularly for patients with null mutations. The ongoing COBALT-1 study is currently evaluating gemcabene in HoFH patients (NCT02722408).
Thirdly, the impaired LDL receptor in HoFH appears to be an ideal target for gene therapy. The prospect of curing HoFH has attracted great interest, and the first study involving five patients was conducted as early as in the 1990s. 12 The results did demonstrate the feasibility of this approach, although the variable and transient response reflected the limitations of the technique at that time. Fortunately, gene therapy for FH is now closer than ever due to technological advances enabling increased transgene expression and reduced immunogenicity. 13 The results of a planned study in which 12 HoFH patients will receive a recombinant adeno-associated virus vector carrying the LDL receptor gene will reveal if the hope that we can cure HoFH sooner or later is justified. The accelerated pace of development of novel therapies for HoFH patients provides hope that we may substantially improve clinical outcomes for these patients in the foreseeable future. Of particular importance is the ongoing commitment to international collaborations which may serve to identify patients for participation in clinical studies, as well as to improve our insight into the disease and regional differences in the management of these patients. Until these efforts have come to fruition, HoFH remains a devastating disease and its consequences can only be limited by early initiation of multimodal treatment. The combination of high-dose statins, ezetimibe, and evolocumab has substantially improved outcomes for these patients, although even this combination enables only a minority of patients to reach acceptable lipid levels. Thompson et al. have now confirmed that the extent of therapeutic cholesterol reduction determines survival in HoFH patients. This conclusion underlined the need for a rigorous, multimodal treatment approach, often including apheresis, until the promising therapies which are under development become available.
